Tango Therapeutics files 8-K for PDAC investor presentation
Tango Therapeutics, Inc. filed an 8-K with the U.S. Securities and Exchange Commission to disclose an investor presentation regarding its participation in the PDAC conference. The filing, dated October 23, 2026, includes an exhibit containing a safe harbor statement that classifies numerous forward-looking statements made by the company and its senior management team. These statements pertain to the anticipated benefits, tolerability, and efficacy of the company's PRMT5 inhibitors, both as standalone treatments and in combination with RAS(ON)-inhibitors. The presentation outlines Tango's regulatory expectations, specifically the belief that the combination of vopimetostat and RAS inhibitors could support a pivotal study in first-line pancreatic cancer and facilitate a path to potential first-line approvals. Management also discussed expectations regarding the company's cash runway and plans for future clinical trials involving vopimetostat and TNG456. A key operational focus mentioned in the disclosure is the expectation to secure sufficient clinical supply of daraxonrasib for a planned Phase 3 trial evaluating vopimetostat in combination with daraxonrasib. The filing notes that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed. Identified risk factors include the possibility that preclinical benefits may not be evident in later studies or broader patient populations, as well as the company's limited experience with conducting clinical trials. Tango relies on third parties to operate its clinical trials and supply drug substance, which is currently sole sourced. The document warns that the company may need to raise capital in the future and that an inability to do so on attractive terms could force delays or discontinuation of development programs. Additional risks cited include potential adverse side effects, dependence on a limited number of third parties for drug production, and the impact of government regulation, including the potential approval of the BIOSECURE Act. The presentation also addresses the potential impact of trade restrictions, sanctions, tariffs, and inflation on the company's financial condition. Investors are directed to Tango's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025, for additional information concerning risks and uncertainties. The company disclaims any duty to update these forward-looking statements, which speak only as of the date they are made. The agenda for the presentation includes an introduction by Malte Peters, MD, who serves as President and Chief Executive Officer.
Tango Therapeutics, Inc. filed an 8-K with the U.S. Securities and Exchange Commission to disclose an investor presentation regarding its participation in the PDAC conference. The filing, dated October 23, 2026, includes an exhibit containing a safe harbor statement that classifies numerous forward-looking statements made by the company and its senior management team. These statements pertain to the anticipated benefits, tolerability, and efficacy of the company's PRMT5 inhibitors, both as standalone treatments and in combination with RAS(ON)-inhibitors. The presentation outlines Tango's regulatory expectations, specifically the belief that the combination of vopimetostat and RAS inhibitors could support a pivotal study in first-line pancreatic cancer and facilitate a path to potential first-line approvals. Management also discussed expectations regarding the company's cash runway and plans for future clinical trials involving vopimetostat and TNG456. A key operational focus mentioned in the disclosure is the expectation to secure sufficient clinical supply of daraxonrasib for a planned Phase 3 trial evaluating vopimetostat in combination with daraxonrasib. The filing notes that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed. Identified risk factors include the possibility that preclinical benefits may not be evident in later studies or broader patient populations, as well as the company's limited experience with conducting clinical trials. Tango relies on third parties to operate its clinical trials and supply drug substance, which is currently sole sourced. The document warns that the company may need to raise capital in the future and that an inability to do so on attractive terms could force delays or discontinuation of development programs. Additional risks cited include potential adverse side effects, dependence on a limited number of third parties for drug production, and the impact of government regulation, including the potential approval of the BIOSECURE Act. The presentation also addresses the potential impact of trade restrictions, sanctions, tariffs, and inflation on the company's financial condition. Investors are directed to Tango's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025, for additional information concerning risks and uncertainties. The company disclaims any duty to update these forward-looking statements, which speak only as of the date they are made. The agenda for the presentation includes an introduction by Malte Peters, MD, who serves as President and Chief Executive Officer.